ERBB2 and breast carcinoma: With the development of anti-HER2 therapies, such as trastuzumab (2), pertuzumab (3), lapatinib (4), neratinib (5), and ado-trastuzumab emtansine (T-DM1) (6), the prognoses of patients with HER2-positive breast cancer have improved significantly.